GSK· @GSK · X·· 16 天前精选AI 评分58
AI 导读
GSK宣布与Chimagen Biosciences签署授权协议，获得一款用于多发性骨髓瘤的在研T细胞衔接器（TCE）。GSK称此举推进其在血液肿瘤领域的领先目标，相关细节见其官网新闻稿。
推荐理由
GSK与Chimagen就多发性骨髓瘤T细胞衔接器达成授权协议，读者可据此了解其在血液肿瘤领域的布局动作。
正文
#News for #investors and #media: We have entered a licence agreement with Chimagen Biosciences for an investigational T-cell engager for multiple myeloma, advancing our leadership ambitions in blood cancer.
Find out more: https://www.gsk.com/en-gb/media/press-releases/gsk-to-acquire-potential-best-in-class-t-cell-engager-tce-for-multiple-myeloma-from-chimagen-biosciences/
来源：GSK · x.com